90 - Optimizing De-Labeling Strategies and Interventions for Beta-Lactam Prescribing

Thursday, October 20, 2022

3:15 PM – 4:30 PM US ET

Location: 201

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Christopher Bland, PharmD, FCCP, FIDSA, BCPS

Clinical Professor
Pharmacy
University of Georgia College of Pharmacy
Savannah, Georgia, United States

Disclosure(s): bioMerieux Inc.: Honoraria (Ongoing); Merck: Advisor/Consultant (Ongoing), Honoraria (Ongoing)
Jamie L. Wagner, PharmD, BCPS, BCIDP

Clinical Associate Professor
University of Mississippi School of Pharmacy
Jackson, MS, United States

Disclosure(s): Shionogi & Co., Ltd.: Advisor/Consultant (Ongoing)

Faculty(s)

Mary Staicu, PharmD

Infectious Diseases Clinical Pharmacy Specialist
Rochester General Hospital
Rochester, NY, United States

Disclosure(s): No financial relationships to disclose

Slides
Kimberly Blumenthal, MD MSc

MD
Department of Medicine, Division of Rheumatology, Allergy, and Immunology
Massachusetts General Hospital
Boston, MA, United States

Disclosure(s): UpToDate: Honoraria (Ongoing)

Slides
Bruce Jones, Pharm.D., FIDSA, BCPS

Infectious Diseases Clinical Pharmacy Specialist
St. Joseph's/Candler Health System
Savannah, Georgia, United States

Disclosure(s): AbbVie: Advisor/Consultant (), Honoraria (); La Jolla: Honoraria (); Melinta: Advisor/Consultant (); Paratek: Honoraria (); Regeneron: Honoraria ()

Slides

Disclosure(s):

Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS: bioMerieux Inc.: Honoraria (Ongoing); Merck: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

Jamie L. Wagner, PharmD, BCPS, BCIDP: Shionogi & Co., Ltd.: Advisor/Consultant (Ongoing)

Mary L. Staicu, PharmD: No financial relationships to disclose

Kimberly G. Blumenthal, MD MSc: UpToDate: Honoraria (Ongoing)

Bruce M. Jones, Pharm.D., FIDSA, BCPS: AbbVie: Advisor/Consultant (), Honoraria (); La Jolla: Honoraria (); Melinta: Advisor/Consultant (); Paratek: Honoraria (); Regeneron: Honoraria ()

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe penicillin allergy de-labeling interventions in low-risk patients, including cross-reactivity assessment;
detail penicillin allergy de-labeling interventions in moderate- or high-risk patients;
initiate and sustain a successful penicillin allergy de-labeling program

Presentations:

3:15 PM – 3:40 PM US ET

Breaking the Chains of the Beta-Lactam Allergy: De-Labeling Strategies for Low-Risk Patients
Speaker: Mary L. Staicu, PharmD – Rochester General Hospital
3:40 PM – 4:05 PM US ET

Intervention Strategies for Moderate- to High-Risk Patients With a Penicillin Allergy Label
Speaker: Kimberly G. Blumenthal, MD MSc – Massachusetts General Hospital
4:05 PM – 4:30 PM US ET

Initiating and Sustaining a Successful Penicillin Allergy De-Labeling Program
Speaker: Bruce M. Jones, Pharm.D., FIDSA, BCPS – St. Joseph's/Candler Health System